Tucker Swan

Tucker Swan’s 35 years of experience spans the pharmaceutical and medical device industry, including roles in consulting, business planning, publishing, and pharmaceutical research. Besides co-founding Aptis Partners, his consulting experience includes The Wilkerson Group, where he focused on cardiovascular devices in his role as Director of Devices for the Company’s Cardiovascular Market Intelligence Service, and as Vice President at Kendall Strategies. He has completed hundreds of projects for clients in the pharma, biotech, medical device, and diagnostic industry, spanning a range of technology evaluations, acquisition analyses, market opportunity assessments, and strategic planning studies.

Prior experience includes roles as Editor of IN VIVO: The Business and Medicine Report as well as a news reporter for MDDI Reports (“The Gray Sheet”). He has held business planning positions in the international pharmaceuticals division at Eli Lilly and Company, the domestic business planning group responsible for Eli Lilly’s diversification into the medical device and diagnostic industry, and with Therics, a start-up company developing a 3D printing process for making medical devices, tissue healing matrices, and drug delivery systems. Tucker started his career as a bench chemist at Squibb Corporation.

AMY ENTWISTLE
Principal, Entwistle Consulting

Amy Entwistle specializes in business strategy, market research, and competitive analysis for early stage pharmaceutical products and medical devices as well as discovery technologies. Her in-depth business and medical experience are derived from hundreds of interviews with physicians, scientists, and thought leaders across a broad range of therapeutic areas as well as analysis of the basic science and clinical literature and industry databases. She has a Master’s degree in Cellular and Molecular Physiology and has worked closely with the partners of Aptis since the firm was founded in 2001. She was previously a Senior Consultant with Kendall Strategies.

PETE LEONE, Chief Business Officer and Board Member, Self-Employed

Pete Leone is a life sciences entrepreneur with over twenty-five years of demonstrated success in bio-pharmaceuticals and medical devices.  Pete consults with various early stage biotechs in business development and strategic transactions and serves on not-for-profit and corporate Boards including SeromYx’s Board of Directors.  Most recently, Pete led business development efforts for Bicycle Therapeutics as Chief Business Officer.

Previously, Pete was the Vice President of Strategic Business Initiatives at Arrowhead Pharmaceuticals, where he led a $3.7 billion deal with Janssen Pharmaceuticals which included $250 million in upfront cash and equity at a premium.  Before that, he was founding CEO or COO at three venture backed companies, including Mersana Therapeutics, where he focused on raising capital and building the company’s platform technology and product pipeline. In his career, Pete has negotiated and managed alliances in twenty-four strategic corporate agreements and nine academic technology licenses, including a $670 million collaboration with Amgen and a $340 million collaboration with Teva.  He has helped several companies from inception to major value creating milestones including validating deals, INDs, clinical development, FDA clearance, payer contracting, patient advocacy, and revenues.  

Early in his career, Pete worked in Systems Engineering at General Electric, in marketing at Procter & Gamble, and was a Partner at Corporate Decisions, now part of Mercer.  Pete holds an A.B. in engineering science with pre-med studies from Dartmouth College and an MBA from the Stanford University Graduate School of Business.

EDWARD BERGER, PhD
Principal, Larchmont Strategic Advisors

Larchmont Strategic Advisors helps life sciences companies create and implement integrated strategies to address the many policy and regulatory obstacles and opportunities they face in their efforts to secure public and private insurer coverage and optimal reimbursement for new or evolving technologies. Edward Berger has more than 30 years of experience working in senior management or as a consultant with medical device, biotechnology, and health services companies, dealing with problems at the intersection of U.S. and international health care policy, corporate strategy development, and strategically sensitive corporate communications with government, investors, and the media.